Alpelisib is primarily used in the treatment of advanced or metastatic breast cancer. It is particularly effective in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer that has mutations in the PIK3CA gene. These mutations lead to the activation of the PI3K pathway, making Alpelisib a targeted therapy for these specific cases.
